Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.
Other Scholarly Work
McMasters, Morgan, Mora, Jorge. (2025). Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.
. 17(10), e94863. 10.7759/cureus.94863
McMasters, Morgan, Mora, Jorge. (2025). Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.
. 17(10), e94863. 10.7759/cureus.94863
Chronic pain is a widespread condition affecting millions globally, placing significant strain on healthcare systems, as evidenced by the current opioid crisis. Despite advances in pain management, conventional treatments often fail to address the underlying inflammatory mechanisms that sustain chronic pain. Recent evidence suggests that metaflammation, or meta-inflammation - defined as a chronic, low-grade inflammatory state driven by metabolic dysregulation - plays a pivotal role in the persistence and exacerbation of chronic pain. This review explores the relationship between meta-inflammation and chronic pain, emphasizing the contribution of inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and IL-1β. Meta-inflammation is induced by metabolic imbalances, poor dietary habits, gut microbiota alterations, and other lifestyle factors, leading to systemic immune activation. Persistent cytokine signaling results in neuroinflammation, promoting central sensitization and heightened pain perception. Chronic diseases such as obesity, diabetes, cardiovascular disease, and endometriosis share common inflammatory pathways with chronic pain, further supporting the role of meta-inflammation in pain pathophysiology. Given the association between metabolic dysfunction and chronic pain, targeting meta-inflammation presents a novel therapeutic approach to pain management. Dietary modifications, such as the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets, supplementation with omega-3 fatty acids, polyphenols, curcumin, and vitamin D, have demonstrated anti-inflammatory and pain-modulating effects. Additionally, lifestyle interventions, such as optimizing sleep quality, and medical management for metabolic dysfunction - such as metformin, glucagon-like peptide-1 (GLP-1) agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors - offer promising avenues for reducing systemic inflammation and chronic pain symptoms. This review underscores the necessity of integrating meta-inflammation management into standard pain treatment protocols. By incorporating targeted dietary, lifestyle, and pharmacologic strategies, clinicians can more effectively address the underlying inflammatory drivers of chronic pain, ultimately improving patient outcomes and reducing reliance on opioids.
